Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Anus Neoplasms 1

Interventions

pembrolizumab 6Cisplatin 5Radiotherapy 4Paclitaxel 3Nivolumab 3lenvatinib 2Specimen Handling 2Platinum 2Papillomavirus Vaccines 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Gemcitabine 2Carboplatin 2CTLA-4 Antigen 2Bleomycin 2Bevacizumab 21,2-diaminocyclohexaneplatinum II citrate 2zimberelimab 1rocakinogene sifuplasmid 1liposomal doxorubicin 1durvalumab 1dostarlimab 1cemiplimab 1belzutifan 1antineoplaston AS 2-1 1antineoplaston A10 1alovudine 1aldesleukin 1Watchful Waiting 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Vulvar Neoplasms × Adoptive Transfer × Clear all
NCT05686226 2026-02-27

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Rutgers, The State University of New Jersey

Phase 2 Recruiting
20 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡